JP2024535868A5 - - Google Patents

Info

Publication number
JP2024535868A5
JP2024535868A5 JP2024517052A JP2024517052A JP2024535868A5 JP 2024535868 A5 JP2024535868 A5 JP 2024535868A5 JP 2024517052 A JP2024517052 A JP 2024517052A JP 2024517052 A JP2024517052 A JP 2024517052A JP 2024535868 A5 JP2024535868 A5 JP 2024535868A5
Authority
JP
Japan
Prior art keywords
cell
nucleic acid
recombinant nucleic
acid molecule
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076618 external-priority patent/WO2023044461A2/en
Publication of JP2024535868A publication Critical patent/JP2024535868A/ja
Publication of JP2024535868A5 publication Critical patent/JP2024535868A5/ja
Pending legal-status Critical Current

Links

JP2024517052A 2021-09-17 2022-09-16 Il-9シグナル伝達ドメインを使用したスイッチ受容体 Pending JP2024535868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245661P 2021-09-17 2021-09-17
US63/245,661 2021-09-17
PCT/US2022/076618 WO2023044461A2 (en) 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains

Publications (2)

Publication Number Publication Date
JP2024535868A JP2024535868A (ja) 2024-10-02
JP2024535868A5 true JP2024535868A5 (cg-RX-API-DMAC7.html) 2025-09-25

Family

ID=83688655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024517052A Pending JP2024535868A (ja) 2021-09-17 2022-09-16 Il-9シグナル伝達ドメインを使用したスイッチ受容体
JP2024517113A Pending JP2024535872A (ja) 2021-09-17 2022-09-16 Il-9シグナル伝達ドメインを使用したスイッチ受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024517113A Pending JP2024535872A (ja) 2021-09-17 2022-09-16 Il-9シグナル伝達ドメインを使用したスイッチ受容体

Country Status (7)

Country Link
US (5) US12202884B2 (cg-RX-API-DMAC7.html)
EP (2) EP4402161A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024535868A (cg-RX-API-DMAC7.html)
CN (2) CN118251410A (cg-RX-API-DMAC7.html)
AU (2) AU2022347445A1 (cg-RX-API-DMAC7.html)
CA (2) CA3232664A1 (cg-RX-API-DMAC7.html)
WO (2) WO2023044457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12291651B2 (en) 2021-04-07 2025-05-06 Wisconsin Alumni Research Foundation Liquid crystal-infused slippery anti-fouling surfaces
CA3231615A1 (en) * 2021-09-17 2023-03-23 Mikko SIURALA Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
WO2025117789A1 (en) * 2023-12-01 2025-06-05 Parker Institute For Cancer Immunotherapy Engineered immune signaling constructs
WO2026024685A1 (en) * 2024-07-23 2026-01-29 Feromics Inc. Uses of immunomodulatory fusion proteins to enhance efficacy of car-expressing immune effector cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO2010006111A2 (en) 2008-07-10 2010-01-14 Merck & Co., Inc. Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
JP7299021B2 (ja) 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
CN109880803B (zh) * 2017-12-06 2024-06-07 恺兴生命科技(上海)有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CN110615843B (zh) 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
JP2020110135A (ja) 2019-01-09 2020-07-27 エーテーハー チューリッヒEth Zurich 汎用細胞外分子センサー
JP2022519704A (ja) 2019-02-08 2022-03-24 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) キメラサイトカイン受容体
GB201911187D0 (en) * 2019-08-05 2019-09-18 Autolus Ltd Receptor
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
WO2021141986A1 (en) 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
US20230138428A1 (en) * 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
JP2023520572A (ja) 2020-04-06 2023-05-17 シンセカイン インコーポレイテッド オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
EP4305054A4 (en) 2021-03-09 2025-03-19 The Trustees of The University of Pennsylvania SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2
EP4082429A1 (en) * 2021-04-28 2022-11-02 Koninklijke Philips N.V. A shell cuff
US11688614B2 (en) * 2021-04-28 2023-06-27 Kla Corporation Mitigating thermal expansion mismatch in temperature probe construction apparatus and method
CA3231615A1 (en) 2021-09-17 2023-03-23 Mikko SIURALA Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
EP4554972A1 (en) 2022-07-11 2025-05-21 The Board of Trustees of the Leland Stanford Junior University Tunable cytokine receptor signaling domains

Similar Documents

Publication Publication Date Title
JP2024535872A5 (cg-RX-API-DMAC7.html)
Curtis et al. T-cell interleukin 1 receptor cDNA expressed in Chinese hamster ovary cells regulates functional responses to interleukin 1.
Pillarisetti et al. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1): SDF-1 α mRNA is selectively induced in rat model of myocardial infarction
Ho et al. A receptor for interleukin 10 is related to interferon receptors.
Hilton et al. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor.
Kitamura et al. Reconstitution of functional receptors for human granulocyte/macrophage colony-stimulating factor (GM-CSF): evidence that the protein encoded by the AIC2B cDNA is a subunit of the murine GM-CSF receptor.
Rajagopalan et al. Structural basis of chemokine receptor function—a model for binding affinity and ligand selectivity
Alles et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes
Horuk The interleukin-8-receptor family: from chemokines to malaria
Cosman et al. A new cytokine receptor superfamily
EP1229047B1 (en) IL-1 Receptor fusion proteins used as antagonists and methods of making and using
Liew et al. The role of innate mediators in inflammatory response
Jordana et al. Immune-inflammatory functions of fibroblasts
Cameron et al. Cytokines, chemokines and their receptors
TWI713798B (zh) 增加介白素-2(il-2)分泌量之方法和源自該方法之蛋白類
Dinarello Targeting interleukin 18 with interleukin 18 binding protein
JP2022536347A5 (cg-RX-API-DMAC7.html)
Thelen et al. Chemokine receptor oligomerization: functional considerations
Liew The role of innate cytokines in inflammatory response
JPH08507676A (ja) 可溶性オリゴマー蛋白質の調製法
RS51602B (sr) April receptor (bcma) i njegova upotreba
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
JP2021527700A5 (cg-RX-API-DMAC7.html)
KR20160108291A (ko) 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
NO317735B1 (no) Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.